INmune Bio fails to meet main goal in Alzheimer's treatment study
https://seekingalpha.com/news/4463660-inmune-bio-fails-to-meet-main-goal-in-alzheimers-treatment-study?source=feed_sector_healthcare
Jun 30, 2025 -
0
INmune Bio Phase 2 MINDFuL Study Of XPro In Alzheimers Disease Fails; Stock Down In Pre-market
https://www.rttnews.com/story.aspx?Id=3549728
Jun 30, 2025 - INmune Bio Inc. (INMB) Monday said that its Phase 2 MINDFuL study of XPro in patients with early Alzheimers Disease (AD) with biomarkers of inflammation did not meet its primary goal. The company's shares were more than 50% down in pre-market.
0
INmune Bio reverses early gains after stock offering
https://seekingalpha.com/news/4463366-inmune-bio-stock-falls-stock-offering?source=feed_sector_healthcare
Jun 27, 2025 -
0
Vor Bio surges after private placement, licensing deal
https://seekingalpha.com/news/4462943-vor-bio-stock-surges-private-placement?source=feed_sector_healthcare
Jun 26, 2025 -
0
Vor Bio announces $175M private placement
https://seekingalpha.com/news/4462458-vor-bio-announces-175m-private-placement?source=feed_sector_healthcare
Jun 25, 2025 -
0
Nuvation Bio jumps after insiders purchase shares worth over $1.1M
https://seekingalpha.com/news/4460315-nuvation-bio-jumps-after-insiders-purchase-shares-worth-over-11m?source=feed_sector_healthcare
Jun 20, 2025 -
0
Third Harmonic Bio gets shareholder nod to wind down operations
https://seekingalpha.com/news/4457617-third-harmonic-bio-stock-gains-investor-nod-wind-down?source=feed_sector_healthcare
Jun 12, 2025 -
0
Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi
https://seekingalpha.com/news/4457354-nuvation-bio-stock-focus-fda-clears-ibtrozi?source=feed_sector_healthcare
Jun 11, 2025 -
0
Cullinan Therapeutics in pact with Genrix Bio for velinotamig
https://seekingalpha.com/news/4455627-cullinan-therapeutics-in-pact-with-genrix-bio-for-velinotamig?source=feed_sector_healthcare
Jun 04, 2025 -
0
Instil Bio Names Jamie Freedman Chief Medical Officer To Advance AXN-2510; Shares Surge
https://www.rttnews.com/story.aspx?Id=3543511
Jun 02, 2025 - Shares of Instil Bio, Inc. (TIL) were surging around 49 percent in the pre-market activity on the Nasdaq after the clinical-stage biopharmaceutical company announced Monday the appointment of Jamie Freedman as Chief Medical Officer.
0
Page 1>